Surgery Websites
Surgical Oncology Program »  Meet the Team »  Surgical Oncology »  Christina Yau, PhD.
Christina Yau, Ph.D.

Christina Yau, Ph.D.

  • Associate Professor of Surgery
  • Division of Surgical Oncology

Contact Information

550 16th. Street, #6350
San Francisco, CA 94158
Phone: 415-502-0134
[email protected]
Orchid: Orchid 000-0002-1937-0859
Open Popup
  Institution  
  Degree    
  Dept or School    
  End Date    
  • University of California, San Francisco
  • Ph.D.
  • Graduate Division (Bioengineering)
  • 2007
  • Dr. Yau is a biostatistician and bioinformaticist focused on the analysis of high dimensional biological data to further our understanding of the mechanisms driving cancer prognosis and treatment. She developed a multigene expression-based prognostic signature for triple negative breast cancers. She is leading the I-SPY 2 statistical team on developing molecular predictors of breast cancer treatment response and risk of recurrence, as well as on innovation in clinical trial design. Dr Yau has mentored 10 pre- or post- doctoral researchers during her career, 7 of whom has continued on to medical school or to careers in translational biomarker research. 

    For trainees that are interested in big data, bioinformatics, and novel trial design, Dr. Yau can serve as a bioinformatics and statistical mentor, and give all trainees the opportunity to learn to use R statistical software. Residents can also work on novel study designs and ways to leverage existing (high dimensional) datasets to address clinical/translational questions of interest.

    MOST RECENT PUBLICATIONS FROM A TOTAL OF 111
    Data provided by UCSF Profiles, powered by CTSI
    1. Shieh Y, Roger J, Yau C, Wolf DM, Hirst GL, Swigart LB, Huntsman S, Hu D, Nierenberg JL, Middha P, Heise RS, Shi Y, Kachuri L, Zhu Q, Yao S, Ambrosone CB, Kwan ML, Caan BJ, Witte JS, Kushi LH, 't Veer LV, Esserman LJ, Ziv E. Development and testing of a polygenic risk score for breast cancer aggressiveness. NPJ Precis Oncol. 2023 May 15; 7(1):42. View in PubMed
    2. Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E, Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ, Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ, DeMichele AM, Rugo HS, van 't Veer LJ. Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy. Cancer Cell. 2023 06 12; 41(6):1091-1102.e4. View in PubMed
    3. Parker BA, Shatsky RA, Schwab RB, Wallace AM, I-SPY 2 Consortium, Wolf DM, Hirst GL, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Ghia EM, Yau C, Kipps TJ. Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial. Breast Cancer Res Treat. 2023 Jun; 199(2):281-291. View in PubMed
    4. Mukhtar RA, Yau C, Esserman LJ. Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply. JAMA Surg. 2023 06 01; 158(6):675. View in PubMed
    5. Magbanua MJM, van 't Veer L, Clark AS, Chien AJ, Boughey JC, Han HS, Wallace A, Beckwith H, Liu MC, Yau C, Wileyto EP, Ordonez A, Solanki TI, Hsiao F, Lee JC, Basu A, Brown Swigart L, Perlmutter J, Delson AL, Bayne L, Deluca S, Yee SS, Carpenter EL, Esserman LJ, Park JW, Chodosh LA, DeMichele A. Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early stage breast cancer: the I-SPY SURMOUNT study. Breast Cancer Res Treat. 2023 Apr; 198(2):383-390. View in PubMed
    6. View All Publications

     

    Site Directory
      X